H19 and central nervous system cancer: The upregulation of H19 in gliomas was clearly interrelated with primary disease (OR=12.20, for LGG vs. GBM), age (OR=4.55, for <55 vs.≥55), cancer status (OR=2.20, for tumor free vs. with tumor), radiation therapy (OR=2.47, for NO vs. YES), grade (OR=2.24, for G2 vs.G3) and new tumor event (OR=1.93, for NO vs. YES) (all P<0.05).